Combination drugs, also known as “fixed-dose combinations” (FDC), provide real clinical benefits when their components work synergistically to enhance their therapeutic effectiveness, improve safety, or minimize the potential for abuse. FDCs are defined as two or more drugs that are packaged together for their administration as a single dosage at a fixed concentration for each component. Each component can be a combination of previously approved drugs, new chemical entities, or both, with each situation requiring its own scope of preclinical studies. At KreaMedica, we work with you to define the preclinical strategy that addresses the pharmacologic and toxicologic needs of your combination drug for its advancement into the clinic.
I have had the pleasure of working with KreaMedica on several programs. They proactively identified and addressed issues and provided regular updates to ensure everyone was on the same page. Their attention to detail and willingness to take ownership of the project’s success makes them invaluable partners. They are great to work with, and I would highly recommend them to anyone looking for a drug development partner.
They supplemented and filled in gaps in our internal network and worked well with our advisors. They truly wanted to contribute to and be part of the project’s success. I highly recommend Claude, Poulomee, and Rudi as reliable partners for planning and executing toxicological and bioanalytical projects.
I have worked with KreaMedica for many years, and I must credit them for the team’s talent, professionalism, and chemistry. That doesn’t happen by accident. As a consultant, I rely on them as the first line to monitor studies and provide proactive solutions when required.